Company profile
4-Antibody (Agenus)
4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform. The Company is making this technology available to pharmaceutical partners and is also using it to generate a proprietary pipeline of antibody therapeutic drugs.
Source: startup.ch
Highlights
Innosuisse Certificate
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
